Pharmacokinetics and biomarker analysis from a phase 1/2 open-label study of the anti-GPC3 T-cell engager SAR444200, in patients with advanced solid tumors

被引：0
|
作者：
Chenard-Poirier, Maxime
Almhanna, Khaldoun
Lim, Darren Wan-Teck
El-Khoueiry, Anthony B.
Samol, Jens
Ryoo, Baek-Yeol
Hong, Jung Yong
Meng, Robin
Abbadessa, Giovanni
Masciari, Serena
Kefsi, Asma
Zhang, Yiding
Guillemin-Paveau, Helene
Pasquier, Benoit
Lepine, Lucie
Dumbrava, Ecaterina Elena
机构：
[1] CHU Quebec Univ Laval, Quebec City, PQ, Canada
[2] Brown Univ, Lifespan Canc Inst, Warren Alpert Med Sch, Providence, RI USA
[3] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[4] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[5] Tan Tock Seng Hosp, Singapore, Singapore
[6] Johns Hopkins Univ, Baltimore, MD USA
[7] Lee Kong Chian NTU, Singapore, Singapore
[8] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[9] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[10] Sanofi, Cambridge, MA USA
[11] Sanofi, Vitry Sur Seine, France
[12] Sanofi, Chilly Mazarin, France
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2579
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors
    Sun, Yuping
    Yu, Jinming
    Tolcher, Anthony W.
    Albany, Costantine
    Chaudhry, Arvind
    Dang, Qi
    Ye, Leiguang
    Yang, Fang
    Liu, Baogang
    Sun, Longhua
    Tang, Jianjun
    Xu, Lei
    Zhu, Xiangyang
    Yang, Yongmin
    Yang, Yang
    Zhan, Yifan
    Li, Benke
    Hou, Kexin
    Zheng, Yang, Sr.
    Wang, Jingjing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function
    Marije Slingerland
    Dagmar Hess
    Sally Clive
    Sunil Sharma
    Per Sandstrom
    Niklas Loman
    Maria G. Porro
    Song Mu
    Edward Waldron
    Sue-zette Valera
    Hans Gelderblom
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1089 - 1098
  • [33] BISPECIFIC T-CELL ENGAGER (BITE®) ANTIBODY BLINATUMOMAB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): AN OPEN-LABEL PHASE 2 STUDY
    Viardot, A.
    Goebeler, M.
    Pfreundschuh, M.
    Adrian, N.
    Libicher, M.
    Hess, G.
    Zettl, F.
    Neumann, S.
    Degenhard, E.
    Stieglmaier, J.
    Zhang, A.
    Nagorsen, D.
    Bargou, R. C.
    HAEMATOLOGICA, 2014, 99 : 154 - 154
  • [34] A phase 1 open-label, dose escalation and expansion trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a Trispecific Humabody® T-cell enhancer, in patients with PSMA plus advanced and/or metastatic solid tumors (POTENTIA).
    de Bono, Johann S.
    Arkenau, Hendrik-Tobias
    Gort, Eelke H.
    Devriese, Lot L.
    Fontana, Elisa
    Knapen, Daan G.
    Tiu, Crescens
    Williams, Anja
    de Groot, Derk Jan A.
    Gunaydin, Ulug M.
    Bartlett, Phillip
    Pierce, Andrew J.
    Bland-Ward, Philip
    Hashimoto, Kenji
    de Vries, E. G. Elisabeth
    CANCER RESEARCH, 2022, 82 (12)
  • [35] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Andrea Wang-Gillam
    William Schelman
    Stacey Ukrainskyj
    Caly Chien
    Martha Gonzalez
    Zhao Yang
    Marek Kania
    Heather Yeckes-Rodin
    Investigational New Drugs, 2023, 41 (6) : 851 - 860
  • [36] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Frederik Marmé
    Carlos Gomez-Roca
    Kristina Graudenz
    Funan Huang
    John Lettieri
    Carol Peña
    Zuzana Jirakova Trnkova
    Jan Eucker
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 727 - 737
  • [37] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Marme, Frederik
    Gomez-Roca, Carlos
    Graudenz, Kristina
    Huang, Funan
    Lettieri, John
    Pena, Carol
    Trnkova, Zuzana Jirakova
    Eucker, Jan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 727 - 737
  • [38] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Wang-Gillam, Andrea
    Schelman, William
    Ukrainskyj, Stacey
    Chien, Caly
    Gonzalez, Martha
    Yang, Zhao
    Kania, Marek
    Yeckes-Rodin, Heather
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 851 - 860
  • [39] A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors
    Liao, Mingxiang
    Jeziorski, Krzysztof G.
    Tomaszewska-Kiecana, Monika
    Lang, Istvan
    Jasiowka, Marek
    Skarbova, Viera
    Centkowski, Piotr
    Ramlau, Rodryg
    Gornas, Maria
    Lee, John
    Edwards, Sarah
    Habeck, Jenn
    Nash, Eileen
    Grechko, Nikolay
    Xiao, Jim J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (05) : 887 - 897
  • [40] Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single Agent in Patients With Refractory Solid Tumors
    Bendell, Johanna C.
    Patel, Manish R.
    Infante, Jeffrey R.
    Kurkjian, Carla D.
    Jones, Suzanne F.
    Pant, Shubham
    Burris, Howard A., III
    Moreno, Ofir
    Esquibel, Vanessa
    Levin, Wendy
    Moore, Kathleen N.
    CANCER, 2015, 121 (07) : 1056 - 1063
12345